Elsevier: Preprints With The Lancet Launches on SSRN
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial - The Lancet
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial - The Lancet Regional Health – Americas
Collaborative Research: Community Health Impact Coalition Lancet Preprint - Research - Community Health Toolkit
How swamped preprint servers are blocking bad coronavirus research
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis - The Lancet Microbe
Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study - The Lancet Infectious Diseases
Efficacy and effectiveness of inactivated vaccines against symptomatic COVID-19, severe COVID-19, and COVID-19 clinical outcomes in the general population: a systematic review and meta-analysis - The Lancet Regional Health – Western Pacific
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial - The Lancet
An interactive website tracking COVID-19 vaccine development - The Lancet Global Health
The Lancet, 14 October 2023, Volume 402, Issue 10410, Pages 1299-1392
Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis - The Lancet Global Health
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression - The Lancet Infectious Diseases
For Authors: Submit your work
Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil - The Lancet
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study - The Lancet
Congrats to Dr. Therriault and team on their amazing preprint in The Lancet! 👏 🧠 | ALZpath Inc. posted on the topic | LinkedIn
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression - The Lancet
Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study - The Lancet
The Lancet Commission on lessons for the future from the COVID-19 pandemic - The Lancet
COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room - The Lancet Microbe
Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system - The Lancet Infectious Diseases
